231 related articles for article (PubMed ID: 31325906)
1. Targeting PDZ-binding kinase is anti-tumorigenic in novel preclinical models of ACC.
Kar A; Zhang Y; Yacob BW; Saeed J; Tompkins KD; Bagby SM; Pitts TM; Somerset H; Leong S; Wierman ME; Kiseljak-Vassiliades K
Endocr Relat Cancer; 2019 Oct; 26(10):765-778. PubMed ID: 31325906
[TBL] [Abstract][Full Text] [Related]
2. Mitotic kinase PBK/TOPK as a therapeutic target for adult T‑cell leukemia/lymphoma.
Ishikawa C; Senba M; Mori N
Int J Oncol; 2018 Aug; 53(2):801-814. PubMed ID: 29901068
[TBL] [Abstract][Full Text] [Related]
3. Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo.
Joel M; Mughal AA; Grieg Z; Murrell W; Palmero S; Mikkelsen B; Fjerdingstad HB; Sandberg CJ; Behnan J; Glover JC; Langmoen IA; Stangeland B
Mol Cancer; 2015 Jun; 14():121. PubMed ID: 26081429
[TBL] [Abstract][Full Text] [Related]
4. Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth.
Kim DJ; Li Y; Reddy K; Lee MH; Kim MO; Cho YY; Lee SY; Kim JE; Bode AM; Dong Z
Cancer Res; 2012 Jun; 72(12):3060-8. PubMed ID: 22523035
[TBL] [Abstract][Full Text] [Related]
5. PDZ binding kinase (PBK) is a theranostic target for nasopharyngeal carcinoma: driving tumor growth via ROS signaling and correlating with patient survival.
Wang MY; Lin ZR; Cao Y; Zheng LS; Peng LX; Sun R; Meng DF; Xie P; Yang JP; Cao L; Xu L; Huang BJ; Qian CN
Oncotarget; 2016 May; 7(18):26604-16. PubMed ID: 27049917
[TBL] [Abstract][Full Text] [Related]
6. PDZ binding kinase, regulated by FoxM1, enhances malignant phenotype via activation of β-Catenin signaling in hepatocellular carcinoma.
Yang YF; Pan YH; Cao Y; Fu J; Yang X; Zhang MF; Tian QH
Oncotarget; 2017 Jul; 8(29):47195-47205. PubMed ID: 28525379
[TBL] [Abstract][Full Text] [Related]
7. Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression.
Xu Y; Dong B; Huang J; Kong W; Xue W; Zhu Y; Zhang J; Huang Y
Oncotarget; 2016 Jan; 7(3):3233-44. PubMed ID: 26673009
[TBL] [Abstract][Full Text] [Related]
8. PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma.
Ma H; Li Y; Wang X; Wu H; Qi G; Li R; Yang N; Gao M; Yan S; Yuan C; Kong B
Cell Death Dis; 2019 Feb; 10(3):166. PubMed ID: 30778048
[TBL] [Abstract][Full Text] [Related]
9. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma.
Satoh K; Zhang L; Zhang Y; Chelluri R; Boufraqech M; Nilubol N; Patel D; Shen M; Kebebew E
Clin Cancer Res; 2016 Jul; 22(14):3458-66. PubMed ID: 26873959
[TBL] [Abstract][Full Text] [Related]
10. Novel Interleukin-6 Inducible Gene PDZ-Binding Kinase Promotes Tumor Growth of Multiple Myeloma Cells.
Ota A; Hanamura I; Karnan S; Inaguma S; Takei N; Lam VQ; Mizuno S; Kanasugi J; Wahiduzzaman M; Rahman ML; Hyodo T; Konishi H; Tsuzuki S; Ikeda H; Takami A; Hosokawa Y
J Interferon Cytokine Res; 2020 Aug; 40(8):389-405. PubMed ID: 32721246
[TBL] [Abstract][Full Text] [Related]
11. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.
Barlaskar FM; Spalding AC; Heaton JH; Kuick R; Kim AC; Thomas DG; Giordano TJ; Ben-Josef E; Hammer GD
J Clin Endocrinol Metab; 2009 Jan; 94(1):204-12. PubMed ID: 18854392
[TBL] [Abstract][Full Text] [Related]
12. Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer.
Laha D; Grant RRC; Mishra P; Boufraqech M; Shen M; Zhang YQ; Hall MD; Quezado M; De Melo MS; Del Rivero J; Zeiger M; Nilubol N
J Exp Clin Cancer Res; 2022 Sep; 41(1):282. PubMed ID: 36151566
[TBL] [Abstract][Full Text] [Related]
13. PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas.
Zhu K; Cheng X; Wang S; Zhang H; Zhang Y; Wang X; Chen Y; Wu J
Front Endocrinol (Lausanne); 2021; 12():706909. PubMed ID: 35126305
[TBL] [Abstract][Full Text] [Related]
14. Gossypetin Inhibits Solar-UV Induced Cutaneous Basal Cell Carcinoma Through Direct Inhibiting PBK/TOPK Protein Kinase.
Wang L; Zhang Z; Ge R; Zhang J; Liu W; Mou K; Lv S; Mu X
Anticancer Agents Med Chem; 2019; 19(8):1029-1036. PubMed ID: 30827262
[TBL] [Abstract][Full Text] [Related]
15. PBK promotes aggressive phenotypes of cervical cancer through ERK/c-Myc signaling pathway.
Ma H; Han F; Yan X; Qi G; Li Y; Li R; Yan S; Yuan C; Song K; Kong B
J Cell Physiol; 2021 Apr; 236(4):2767-2781. PubMed ID: 33184870
[TBL] [Abstract][Full Text] [Related]
16. Development of new preclinical models to advance adrenocortical carcinoma research.
Kiseljak-Vassiliades K; Zhang Y; Bagby SM; Kar A; Pozdeyev N; Xu M; Gowan K; Sharma V; Raeburn CD; Albuja-Cruz M; Jones KL; Fishbein L; Schweppe RE; Somerset H; Pitts TM; Leong S; Wierman ME
Endocr Relat Cancer; 2018 Apr; 25(4):437-451. PubMed ID: 29371329
[TBL] [Abstract][Full Text] [Related]
17. Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.
Zhu Y; Wang M; Zhao X; Zhang L; Wu Y; Wang B; Hu W
Oncotarget; 2017 Apr; 8(14):22825-22834. PubMed ID: 28423559
[TBL] [Abstract][Full Text] [Related]
18. Thapsigargin induces apoptosis in adrenocortical carcinoma by activating endoplasmic reticulum stress and the JNK signaling pathway: an in vitro and in vivo study.
Wu L; Huang X; Kuang Y; Xing Z; Deng X; Luo Z
Drug Des Devel Ther; 2019; 13():2787-2798. PubMed ID: 31496655
[TBL] [Abstract][Full Text] [Related]
19. MAPK/ERK pathway inhibition is a promising treatment target for adrenocortical tumors.
Pereira SS; Monteiro MP; Costa MM; Ferreira J; Alves MG; Oliveira PF; Jarak I; Pignatelli D
J Cell Biochem; 2019 Jan; 120(1):894-906. PubMed ID: 30256438
[TBL] [Abstract][Full Text] [Related]
20. GPER agonist G-1 decreases adrenocortical carcinoma (ACC) cell growth in vitro and in vivo.
Chimento A; Sirianni R; Casaburi I; Zolea F; Rizza P; Avena P; Malivindi R; De Luca A; Campana C; Martire E; Domanico F; Fallo F; Carpinelli G; Cerquetti L; Amendola D; Stigliano A; Pezzi V
Oncotarget; 2015 Aug; 6(22):19190-203. PubMed ID: 26131713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
